Clinical Genetic Testing
A major mission of the Iowa Institute of Human Genetics (IIHG) is to bring personalized genomic medicine to patients across Iowa, and beyond. The broad clinical expertise at the University of Iowa Hospitals and Clinics has the unique potential to offer diagnostic genetic testing platforms that target specific phenotypes or patient groups. These tests will be developed by the Research Division of the IIHG before their implementation by the Clinical Diagnostic Division of the IIHG.
The Clinical Diagnostic Division is currently validating two testing platforms. The first test targets genetic renal diseases, while the second test is a pharmacogenetic test specific for clopidogrel metabolism. Whole exome sequencing is being developed through collaboration with the Clinical Diagnostic Division of the IIHG. In addition, a genetic dysmorphology panel is under development by the Research Division of the IIHG.
Targeted Genomic Sequencing
- Genetic Dysmorphology Panel- in development
- Genetic Renal Diseases Panel- in validation
Pharmacogenetic Testing
- CYP2C19 for Clopidogrel efficacy- in validation
Whole Exome Sequencing
If you are interested in partnering with the IIHG for potential test development, please contact the iihg@uiowa.edu or Richard Smith at richard-smith@uiowa.edu.